System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Henri Montaudié is an expert in Dermatology at Centre Hospitalier Universitaire de Nice (France). As of September 2026, ScienceLeadR ranks Henri Montaudié in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Henri Montaudié has authored 252 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 6 of them ongoing. SLR score: 1,110 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Henri Montaudié Centre Hospitalier Universitaire de Nice France
1 110 ScienceLeadR Reputation 1110

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Hôpital l'Archet

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 252

Citations

Citations: 2 717 1st author: 27 Last author: 40 Unique author: 3

Main journals

Ann Dermatol Venereol 46
Annales de Dermatologie et de Vénéréologie - FMC 27
J Eur Acad Dermatol Venereol 27
Annales de dermatologie et de vénéréologie, FMC 16
J Am Acad Dermatol 13

Best Journals

J Clin Oncol 12
Ann Oncol 6
Mol Cancer 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
PMID 42372635 — melanoma, neoplasms, cohort studies, therapeutics		Eur J Cancer20260
Efficacy of ruxolitinib cream in a patient with lupus miliaris disseminatus faciei.
PMID 42169963		JAAD Case Rep20260
Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.
PMID 42136087 — melanoma, brain, retrospective studies, neoplasms, drug therapy, neoplasm metastasis, therapeutics, mutation, prognosis, chemotherapy		Cancer Med20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 10
N/A 6
Phase 3 4
Phase 1 2

By status:

Completed 9
Recruiting 6
Active not recruiting 5
Terminated 1
Unknown 1

By type:

Interventional 19
Observational 3

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 1
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of V940 and pembrolizumab in people with melanoma (V940 012)
2024-519605-36-00 — melanoma, rna, messenger		Phase 2Recruiting2025
Phase 1 Study of IMC P115C in Advanced PRAME Positive Cancers
2023-509767-25-00 — neoplasms		Phase 1Recruiting2024
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
NCT05649683 — cytokines, skin, melanoma, neoplasms, immunotherapy, aftercare, drug-related side effects and adverse reactions, therapeutics		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS